文献速递冠心病血脂与心血管预防

依洛尤单抗在多支与无多支冠状动脉病变患者中的长期疗效

Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

FOURIER随机对照试验及其开放标签延长期FOURIER-OLE评估依洛尤单抗在伴或不伴多支冠状动脉病变(MVD)患者中的长期获益。在FOURIER中,MVD患者主要终点风险降低23%(HR 0.77),无MVD患者降低11%(HR 0.89);延长期随访显示获益随时间增大。结论支持两类患者均早期启动强化降LDL-C治疗。

要点

  • 依洛尤单抗在伴或不伴MVD的冠心病患者中均降低主要不良心血管事件风险。
  • MVD患者从依洛尤单抗治疗中获益更早且幅度更大,但无MVD患者获益随时间增长。
  • 研究支持对冠心病患者无论是否合并MVD均早期启动强化降LDL-C治疗。

核心结论

  • 依洛尤单抗在伴或不伴多支冠状动脉病变的冠心病患者中均降低主要不良心血管事件风险。
  • MVD患者的获益倾向于出现更早且幅度更大,但两组获益均随时间延长而增大。
  • 数据支持在伴或不伴MVD的患者中早期启动强化低密度脂蛋白胆固醇降低治疗。

研究设计与样本

  • FOURIER随机对照试验将27,564例患者随机分配至依洛尤单抗组或安慰剂组,其中6,635例进入FOURIER-OLE开放标签延长期。
  • FOURIER中23,656例冠心病患者按是否存在MVD(≥2支大血管狭窄≥40%)分类,其中25.4%有MVD。
  • FOURIER-OLE提供额外中位5年随访;FOURIER中位随访2.2年。

主要发现

  • 在FOURIER中,初始分配至依洛尤单抗组的主要终点风险降低在MVD患者中为23%(HR 0.77,95% CI 0.68-0.87),无MVD患者为11%(HR 0.89,95% CI 0.82-0.96)。
  • 关键次要终点风险降低在MVD患者中为31%(HR 0.69,95% CI 0.59-0.81),无MVD患者为15%(HR 0.85,95% CI 0.77-0.94)。
  • 交互作用P值分别为0.062(主要终点)和0.031(关键次要终点)。
  • 获益幅度在最初数年内倾向于增大,MVD患者风险降低达37%至38%,无MVD患者达23%至28%。

临床怎么用

  • 对伴或不伴MVD的冠心病患者,均应考虑早期启动依洛尤单抗等强化降LDL-C治疗以降低心血管事件风险。
  • MVD患者可能从早期强化降脂治疗中获益更显著,应优先识别并积极干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), during a median follow-up of 2.2 years, risk reduction for major adverse cardiovascular event with evolocumab was greater in patients with multivessel disease (MVD). The FOURIER Open-Label Extension (FOURIER-OLE) provides an additional median follow-up of 5 years. OBJECTIVES: The purpose of this study was to assess the long-term benefit of evolocumab in patients with and without MVD. METHODS: FOURIER randomized 27,564 patients to evolocumab vs placebo; 6,635 entered FOURIER-OLE. Patients with coronary artery disease were categorized based on the presence of MVD (≥40% stenosis in ≥2 large vessels). The primary endpoint was cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; the key secondary endpoint was cardiovascular death, myocardial infarction, or stroke. RESULTS: Of 23,656 patients in FOURIER with coronary artery disease, 25.4% had MVD; 5,887 patients continued into FOURIER-OLE. The risk reduction with initial allocation to evolocumab tended to be greater in patients with MVD than in those without: 23% (HR: 0.77 [95% CI: 0.68-0.87]) vs 11% (HR: 0.89 [95% CI: 0.82-0.96]) for the primary and 31% (HR: 0.69 [95% CI: 0.59-0.81]) vs 15% (HR: 0.85 [95% CI: 0.77-0.94]) for the key secondary endpoints (Pinteraction = 0.062 and Pinteraction = 0.031, respectively). The magnitude of benefit tended to grow during the first several years, reaching 37% to 38% reductions in risk in patients with MVD and 23% to 28% reductions in risk in patients without MVD. CONCLUSIONS: Evolocumab reduced the rate of major adverse cardiovascular event in patients with and without MVD. The benefit tended to occur earlier and was larger in patients with MVD. However, the magnitude grew over time in both groups. These data support early initiation of intensive low-density lipoprotein cholesterol lowering both in patients with and without MVD.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. McClintick DJ, O'Donoghue ML, De Ferrari GM, et al. Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease. J Am Coll Cardiol. 2024. PMID: 38325990. doi:10.1016/j.jacc.2023.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。